No Data
Japanese stock buybacks this week (11/11~11/15)
――――11/11――――$KYB(7242.JP)$ will buy back up to 4.6 million shares, 18.4% of its outstanding shares (excluding its own shares), for an amount of JPY¥ 20 billion.$Persol Holdings(2181.JP)$ will
Mitsubishi UFJ and others announced share buyback on November 14th.
The stocks that announced the establishment of a share buyback framework on November 14 (Thursday) are as follows: <8306> Mitsubishi UFJ 2.3 million shares (2.0%) 300 billion yen (24/11/15-25/3/31) <8316> Mitsui Sumitomo 60 million shares (1.5%) 150 billion yen (24/11/15-25/1/31) <8411> Mizuho 50 million shares (1.9%) 100 billion yen (24/11/15-25/2/28) <7181> Japan Post 30 million shares (7.8%) 35 billion yen (24/11
W Tokyo: Summary of financial results for the 1st quarter of the fiscal year ending June 2025 [Japanese GAAP] (unconsolidated)
W Tokyo: Presentation of financial results for the first quarter of the fiscal year ending June 2025
Japan Postal Service, Japan Post Bank, Mizuho, Dai-ichi Life HD (14th) (5010-9994)
Please note that the above calendar is just a schedule and is subject to change due to company circumstances.--------------------------------------- November 14 (Thursday) <5010> Nippon Seiro <5027> AnyMind G <5029> Circlace <5033> Nulab <5034> unerry <5038> eWeLL <5074> Tes HD <5101>
Emerging markets stocks digest: Fulta continues to rise significantly, sea U sea hits the daily limit.
<4598> DELTA-P 533 +47 surged significantly. After the trading on the 28th, the progress of the phase 1/2 clinical trial of DFP-10917 and VEN was announced, which is considered a positive development. DFP-10917, when given as a low-dose continuous infusion, is believed to be highly safe, stops cancer cells in the G2/M phase, and induces apoptosis (programmed cell death). Therefore, a strong synergistic effect can be expected when combined with VEN (a BCL-2 inhibitor). Currently, a phase 1 clinical trial is underway.
No Data
No Data